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Background: Plasmodium falciparum strains that are resistant to standard-dose chloroquine can be treated by
higher chloroquine concentrations maintained for a longer time in vivo.
Objectives: To determine the relative importance of chloroquine concentrations versus exposure time for elimination of chloroquine-susceptible and -resistant P. falciparum in vitro.
Methods: Chloroquine-susceptible (3D7) and -resistant (FCR3) strains were exposed in vitro to 1, 2, 4, 8, 16 or 32
times their respective 90% inhibitory chloroquine concentrations for 3, 5, 7 or 14 days and then followed until
recrudescence, or not, by 42 days after the end of exposure.
Results: Exposure to chloroquine appeared to eliminate susceptible and resistant parasites, leaving small pyknotic
apparently dead parasites. Chloroquine-susceptible and -resistant parasites recrudesced after 3 and 5 days of
chloroquine exposure. Recrudescence occurred in one out of four 7 day exposure series but not after 14 days exposure. The median time to recrudescence was 13 to 28 days with a range of 8 to 41 days after the end of exposure.
Time to recrudescence after the end of exposure increased with duration of exposure for susceptible and resistant
strains (P , 0.001). Time to recrudescence did not correlate with concentrations greater than 1× IC90.
Conclusions: Chloroquine-susceptible and -resistant P. falciparum probably become dormant. Elimination of
dormant parasites is primarily dependent upon the duration of chloroquine exposure. Exposure to effective
drug concentrations for 7 days eliminates most parasites in vitro. The results support in vivo data indicating
that elimination of chloroquine-resistant P. falciparum correlates with Day 7 chloroquine concentrations.

Introduction
Malaria causes an estimated 409000 deaths and 229 million episodes of illness each year.1 Resistance to the currently recommended artemisinin-based combination therapy has developed
and is spreading.1–4 Our understanding of drug resistance and
potential countermeasures needs to be improved and new treatment options need to be continuously evaluated. Data from
Guinea-Bissau indicating that chloroquine-resistant Plasmodium

falciparum can be eliminated by higher and well-tolerated chloroquine doses are therefore of considerable interest.5–10
In Guinea-Bissau, there was a linear correlation between
Day 7 chloroquine concentrations and in vivo treatment outcome. This peaked at 96% adequate clinical and parasitological
response when P. falciparum that were resistant to standarddose chloroquine were treated with up to double the standard
dose of chloroquine.10 Moreover, parasite densities of
chloroquine-susceptible and -resistant P. falciparum decreased
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Chloroquine-susceptible and -resistant Plasmodium falciparum strains
survive high chloroquine concentrations by becoming dormant but are
eliminated by prolonged exposure

Ursing et al.

Methods
Parasite strains and cultivation
P. falciparum strains 3D7 (chloroquine susceptible) and FCR3 (chloroquine
resistant) were used in this study. Their chloroquine susceptibility phenotypes are matched by allelic differences in well-known modulators of
chloroquine response. Speciﬁcally, the position 72–76 haplotypes in the
P. falciparum chloroquine resistance transporter gene (pfcrt) are
CVMNK and CVIET in 3D7 and FCR3, respectively. Both strains have a
single copy of the P. falciparum multidrug resistance gene 1 (pfmdr1)
and the allelic 86, 184, 1034, 1042, 1246 haplotypes are NYSND and
YYSND for 3D7 and FCR3, respectively. Both strains were maintained in
malaria culture medium RPMI-1640 (Gibco®/Invitrogen™) supplemented with 2 g/L sodium bicarbonate (Gibco®/Invitrogen™), 2 mM
®
®
L-glutamine (Gibco /Invitrogen™), 10 μg/mL gentamicin (Gibco /
Invitrogen™), at 5% haematocrit with human O positive erythrocytes
and 10% human AB positive serum according to standardized methods.26 The erythrocytes were donated by the Department of
Transfusion Medicine at Karolinska University Hospital, washed twice
with PBS and a third time with malaria culture medium. Aliquots were
stored in 15 mL tubes at 4°C for up to 3 weeks. The 3D7 and FCR3 strains
were kindly provided by the late D. Walliker, Department of Animal and
Population Genetics, University of Edinburgh, UK.

In vitro drug susceptibility assays
The IC90 for the chloroquine-susceptible parasite strain 3D7 and the
chloroquine-resistant strain FCR3 were assessed by measuring P. falciparum histidine-rich protein 2 (PfHRP2) using a double-site sandwich
ELISA followed by non-linear regression analysis, as described previously.27 Brieﬂy, ring-stage parasites were incubated at 37°C with
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0.05% starting parasitaemia and 1.5% haematocrit across a range of
chloroquine diphosphate (Sigma–Aldrich) concentrations. After 72 h of
incubation, cell lysis for ELISA analysis was performed by freeze/thawing
the parasites. At least six independent assays were performed for each
strain. Chloroquine IC90 concentrations were assessed in both strains
prior to the start of each series of experiments and were consistently
found to be 60 (95% CI 45–73) and 1000 (95% CI 946–1193) nmol/L
for 3D7 and FCR3, respectively. Chloroquine IC90 concentrations were
also assessed in strains that recrudesced. Chloroquine IC90 concentrations remained unchanged but the data were lost prior to the preparation of this manuscript and can therefore not be presented.

Experimental assays to determine the
time-versus-concentration dependency of parasite
elimination
Unsynchronized cultures of chloroquine-susceptible (3D7) and -resistant
(FCR3) P. falciparum strains were diluted to approximately 1% parasitized
erythrocytes and placed in 6-well culture plates with 5% haematocrit and
a total culture volume of 5 mL (Figure 1). The 3D7 and FCR3 strains were
then exposed to 1, 2, 4, 8, 16 or 32 times their respective chloroquine
IC90 values for 3, 5, 7 or 14 days. Follow-up was for 42 days after the end
of exposure or until recrudescence, which was deﬁned as exponential
growth at ≥1% parasitized erythrocytes. The 6-well culture plates were
kept in candle jars and incubated at 37°C. Thin smears were examined to
determine the proportion of parasitized erythrocytes and the presence or
absence of pyknotic parasites during treatment and follow-up by counting
the number of infected erythrocytes per 2000 erythrocytes. The frequency
of pyknotic parasites was not determined as the frequency was very low.
Four series (A, B, C and D) of experiments were done as outlined below
and in Figure 1. Parasites were maintained in continuous culture in between series.
(A) 3D7 and FCR3 clones were exposed to 1, 2, 4, 8, 16 or 32× IC90 for 3,
5 and 7 days.
(B) 3D7 and FCR3 clones were exposed to 1, 2, 4, 8, 16 or 32× IC90 for 3,
5, 7 and 14 days.
(C) 3D7 and FCR3 clones were exposed to 1, 2, 4, 8, 16 or 32× IC90 for 7
and 14 days.
(D) The Series C experiment was run in duplicate.
The 3, 5, 7 or 14 days of drug exposure were initiated by pipetting off
all RPMI medium from the cultures in the 6-well plates and replacing
the removed medium with complete medium containing chloroquine.
The chloroquine concentrations in the complete medium were 1, 2, 4,
8, 16 or 32 times the 3D7 and FCR3 strains’ respective IC90 values.
Chloroquine-containing medium was removed once daily and replaced
with fresh chloroquine-containing medium for the duration of exposure
(3, 5, 7 or 14 days). Chloroquine-containing medium was removed at
the end of exposure and cultures were washed in PBS and centrifuged
three times at 1500 rpm for 2 min. After washing, the cultures were
placed in new 6-well plates with complete chloroquine-free medium.
In Series A and B, the sampling procedure was as follows: medium
was removed and 2 μL of the remaining erythrocyte-rich mixture were
taken to make a thin smear for Giemsa staining. Fresh medium (with
or without chloroquine) was added. The culture was swirled to create a
suspension. Two hundred microlitres of the suspension was taken for
PfHRP2 ELISA measurements.27 Sampling was done after removal of
old medium and addition of fresh medium to minimize the effect of remaining PfHRP2 from dead P. falciparum in the medium. Sampling for microscopy and PfHRP2 analysis was done daily (Days 0–7) and then every
second day until the ﬁrst signs of parasite growth, after which daily sampling was again done.
Series B included a 14 day exposure due to growth after exposure for
3, 5 and 7 days in Series A. As no growth was detected after 7 and
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at the same rate in vivo when treated with double the standard
dose of chloroquine.10 Attained concentrations were thus sufﬁcient to kill susceptible and resistant P. falciparum. Concurrent
with routine use of well-tolerated triple standard-dose chloroquine, split into 2–3 daily doses for 5 days, the frequency of
chloroquine-resistant P. falciparum was low and stable at 25%
in Guinea-Bissau until replaced by artemether/lumefantrine.8,11,12
Resistance to standard-dose chloroquine did thus not confer a selective advantage when high-dose chloroquine was routinely
used and highly resistant parasites did not become prevalent.
Consequently, the PCR-corrected Day 28 adequate clinical and
parasitological response of double-dose chloroquine taken as
two daily doses for 3 days was 95% in 2008.9
The principal mechanism of P. falciparum resistance to
standard-dose chloroquine appears to be removal of the drug
from its site of action by the P. falciparum chloroquine resistance
transporter (PfCRT).13,14 Higher chloroquine concentrations can
overcome this mechanism, probably accounting for decreasing
parasite densities when ‘resistant’ P. falciparum were treated with
chloroquine.15 Despite apparent in vivo elimination of P. falciparum,
treatment failures occurred in children with low Day 7 chloroquine
concentrations infected with parasites that were resistant to
standard-dose chloroquine.9,10 This is generally considered to be
the result of submicroscopic levels of P. falciparum that survive
treatment.16 A less-explored aspect of parasite survival is the ability
of P. falciparum to become dormant when exposed to multiple different antimalarials.16–25 This study aimed to determine the relative importance of concentration versus time for the elimination
of chloroquine-susceptible and -resistant P. falciparum.

Prolonged chloroquine exposure eliminates dormant P. falciparum

14 days exposure in Series B, strains were only exposed for 7 and 14 days
in Series C and D. To minimize the potential effects of sampling in Series C
and D, no samples for PfHRP2 analyses were taken and sampling for microscopy only was done daily (Days 0 to 5) and then with approximately
72 hourly intervals until the end of follow-up.
To compensate for losses due to sampling and to provide fresh erythrocytes for parasites growing later during the follow-up, medium
(with or without chloroquine) and haematocrit were adjusted to the initial conditions after each sampling.

Statistics
Time to recrudescence, PfHRP2 OD values, exposure time and chloroquine concentrations were analysed as continuous variables and parasite strain as a dichotomous variable. Medians, 95% CIs and IQRs of
continuous variables were estimated using quantile regression with
bootstrapping (100 repeats). Quantile regressions with bootstrapping
(100 repeats) were used to assess the correlation between chloroquine
concentrations and duration of exposure with time to recrudescence
and PfHRP2 concentrations.

Results
The effect of chloroquine concentration and exposure
time on parasite recrudescence
The times from the end of chloroquine exposure until recrudescence, or not, are shown in Table 1 and Figures S1 and S2

(available as Supplementary data at JAC Online). Recrudescence
did not occur after 14 days of chloroquine exposure and only in
one of four series of experiments after 7 days of exposure, irrespective of the drug concentration and strain. The median times
to recovery for chloroquine-resistant (FCR3) and -susceptible
(3D7) strains after the end of exposure to chloroquine for 3, 5
and 7 days were 13 versus 15 (P = 0.09), 19 versus 28 (P = 0.01)
and 21 versus 27 (P = 0.92) days, respectively. Exposure time
was signiﬁcantly linked to time to recrudescence for chloroquinesusceptible (P , 0.001) and chloroquine-resistant (P , 0.001) P.
falciparum.
Time until recrudescence of chloroquine-resistant parasites
(FCR3) was not signiﬁcantly affected by chloroquine concentrations (1–32× IC90), irrespective of whether each exposure time
(3, 5 or 7 days) was assessed separately or exposure times
were pooled. Recovery time increased signiﬁcantly with increasing chloroquine drug concentrations in chloroquine-susceptible
parasites (3D7) exposed for 3 (P = 0.002) and 5 days (P = 0.003)
but not 7 days. However, the signiﬁcance of this correlation disappeared if the 1× IC90 exposure was not included in the calculation. IC90 values did not correlate with recovery time when
chloroquine-resistant and -susceptible strain data were pooled.
Several important additional points should be highlighted. In
the 1× IC90 exposure in Series A, recrudescence occurred faster
after 3 and 5 days of chloroquine exposure compared with higher concentrations (Table 1, Figures S1 and S2). The proportion of

Table 1. Time to P. falciparum recrudescence, deﬁned as exponential growth at ≥1% parasitized erythrocytes, after chloroquine exposure
Clone
Exposure time (days)
Experimental series
1× IC90
2× IC90
4× IC90
8× IC90
16× IC90
32× IC90
Median (95% CI) RT

3D7 (chloroquine susceptible)
3
A, B
8 (5, 10)
15 (14, 15)
16 (15, 16)
16 (15, 17)
17 (16, 18)
17 (17, 17)
15 (13–17)

5
A, B
16
26
28
32
32
33
28

(14, 18)
(23, 28)
(24, 32)
(28, 35)
(30, 34)
(32, 34)
(23–33)

7
A, B, C, D
(26, NR, NR, NR)
(26, NR, NR, NR)
(27, NR, NR, NR)
(27a, NR, NR, NR)
(29, NR, NR, NR)
(41, NR, NR, NR)
27 (26–39)

FCR3 (chloroquine resistant)
14
B, C, D
(NR,
(NR,
(NR,
(NR,
(NR,
(NR,
NR

NR, NR)
NR, NR)
NR, NR)
NR, NR)
NR, NR)
NR, NR)

3
A, B

5
A, B

7
A, B, C, D

14
B, C, D

13 (12, 13)
13 (12, 13)
13 (12, 13)
13 (12, 14)
14 (12, 16)
16 (14, 18)
13 (11–15)

20 (21, 19)
18 (18, 18)
17 (16, 18)
23 (17, 29b)
23 (18, 28b)
29 (30, 28b)
19 (12–25)

(21, NR, NR, NR)
(21, NR, NR, NR)
(20, NR, NR, NR)
(21, NR, NR, NR)
(30, NR, NR, NR)
(36, NR, NR, NR)
21 (20–35)

(NR, NR, NR)
(NR, NR, NR)
(NR, NR, NR)
(NR, NR, NR)
(NR, NR, NR)
(NR, NR, NR)
NR

Data show median time to recrudescence (RT), in days, followed by each experimental series recovery time in brackets. NR denotes no recrudescence
during 42 days of follow-up.
a
Reached 0.7% then growth failed.
b
Reached 1%–2.5% parasitized erythrocytes, then growth failed.
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Figure 1. Experimental design. CQ, chloroquine. This ﬁgure appears in colour in the online version of JAC and in black and white in the print version of
JAC.

Ursing et al.

3D7-parasitized erythrocytes at the start of Series A was 1.5%
compared with 0.9%–1.1% for Series B and C, possibly contributing to this difference. Series A should also be highlighted as both
clones recrudesced after 7 days of exposure. This also occurred
in a pilot study in which 3D7 parasites were exposed to 1, 2, 4
and 8× IC90 concentrations. Finally, at the extreme end of the
spectrum, the chloroquine-susceptible strain recrudesced
41 days after the end of exposure to 32× IC90 for 7 days.

The effect of concentration and exposure time on
parasite clearance
PfHRP2 levels in chloroquine-susceptible (3D7) and -resistant
(FCR3) P. falciparum during and after exposure to 1–32× IC90 for
3, 5 or 7 days are shown in Figure 2. PfHRP2 increased between
Days 0 and 1 (P , 0.01) and then steadily decreased (P , 0.001)
from Days 1 to 7 in chloroquine-resistant parasites. PfHRP2 decreased (P , 0.001) between Days 0 and 7 in chloroquinesusceptible parasites exposed to more than 1× IC90, whereas
PfHRP2 increased between Days 0 and 1 and then decreased in
susceptible parasites exposed to 1× IC90. The decrease continued
in both susceptible and resistant parasites irrespective of exposure
for 3, 5 or 7 days. The rate of decrease was not affected by the
concentration of chloroquine that was used (P = 0.45).

Dormancy
When monitored during and after drug exposure, both
chloroquine-susceptible and -resistant parasites appeared to
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die, leaving only small pyknotic apparently dead parasites. The
pyknotic parasites remained in the erythrocytes and the frequency gradually decreased over time. The exact frequency
could not be reliably determined as pyknotic parasites were
very rare. The ﬁrst signs of resurgence appeared to be pyknotic
parasites developing a very thin layer of presumably cytoplasm
that gradually increased in size until a recognizable live parasite
developed (Figure 3). The process was as previously described by
Teuscher et al.22

Discussion
This study was prompted by in vivo studies showing that
chloroquine-resistant malaria can be overcome by the use of
higher total doses of chloroquine.5,6,8–10 The study aimed to determine the relative importance of chloroquine concentrations
versus exposure time for elimination of chloroquine-susceptible
and -resistant P. falciparum. A 42 day follow-up was used to
match the in vivo follow-up recommended for detection of
recrudescent P. falciparum.28,29 Treatment with chloroquine
most probably induced dormancy or selected parasites in a
dormant stage, in line with previous studies and other antimalarials.16–25 Dormancy occurred in both chloroquine-susceptible
and -resistant P. falciparum, matching ﬁndings in artemisininsusceptible and -resistant P. falciparum.24 Strikingly, and to our
knowledge previously not shown in vitro, parasites recrudesced
up to 41 days after the end of treatment. Dormancy is thus a
pathway of probably underestimated importance by which
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Figure 2. PfHRP2 levels in chloroquine-susceptible (3D7) and -resistant (FCR) P. falciparum during and after exposure to 1–32× IC90 for 3, 5 or 7 days.

Prolonged chloroquine exposure eliminates dormant P. falciparum

P. falciparum strains can survive chloroquine therapy even
though they are susceptible to attained drug concentrations.
As most antimalarials appear to induce dormancy it appears to
be an innate survival mechanism that must be overcome if treatment is to be successful.
All cultures recovered after 3 and 5 days of drug exposure, irrespective of chloroquine concentrations. Recrudescence only
occurred in one out of four series (plus a pilot study) after
7 days of exposure and did not occur after 14 days of exposure,
suggesting that 7 days of drug exposure was sufﬁcient to eliminate the majority of dormant P. falciparum. This matches in vivo
data indicating that minimal parasiticidal drug concentrations
must be maintained for four 48 h cycles and that Day 7 quinoline
concentrations are predictive of treatment outcome when treating susceptible and resistant P. falciparum.10,30 Time over
minimal parasiticidal concentration is thus the primary determinant for treating both chloroquine-susceptible and -resistant
P. falciparum.
The chloroquine concentration that needs to be maintained for
at least 7 days only has to be above IC90. The in vitro IC90 of
1000 nmol/L for chloroquine-resistant P. falciparum in this study
does not automatically apply in vivo. However, parasite densities
of both susceptible and resistant P. falciparum decreased at
the same rate in children with whole-blood chloroquine
concentrations of approximately 3000 nmol/L.9,31 Moreover,
chloroquine-resistant parasites were eliminated and 96% of children cured when Day 7 whole-blood chloroquine concentrations
were 1600 nmol/L and recrudescence was not seen when the
Day 7 concentrations were greater than 1900 nmol/L in vivo.10
Moreover, similar time-dependent but concentration-independent parasite elimination was shown with Plasmodium berghei in
a mouse model.25 In vitro and in vivo data thus match and it is
probable that blood chloroquine concentrations of 2000–

3000 nmol/L for at least 8 days should be effective for in vivo
treatment of chloroquine-resistant P. falciparum.
The concentrations above were well tolerated and attained in
children taking double- or nearly triple-dose chloroquine split
into two daily doses for 3 and 5 days, respectively. Median
peak concentrations in adults taking standard-dose chloroquine
were 3400 (range 1400–5600) nmol/L and the median
steady-state chloroquine concentration in patients treated for
rheumatoid arthritis was approximately 2000–2500 nmol/
L.32,33 The 2000–3000 nmol/L range is thus within this very welltolerated concentration range, indicating that this is a realistic
treatment option.
A common concern is that the use of higher doses will rapidly
select highly resistant P. falciparum. However, the prevalence of
P. falciparum resistant to standard-dose chloroquine was low
and stable at approximately 25% and highly resistant P. falciparum were not detected during the decades that high-dose
chloroquine was used in Guinea-Bissau.12,34 Routine use of highdose chloroquine thus apparently countered the spread of P. falciparum resistant to standard-dose chloroquine, probably by
elimination of dormant P. falciparum that consequently lost
much of their selective advantage. Thus, maintaining
parasiticidal chloroquine concentrations for at least 7 days may
delay the development of resistance, in line with previous
suggestions.30
The increase of PfHRP2 (parasite biomass) during the ﬁrst 24 h
in chloroquine-susceptible P. falciparum exposed to 1× IC90, as
opposed to the decrease seen after exposure to 2× IC90 and
higher concentrations, is probably related to the method by
which IC90 was established, which utilized a lower proportion
of parasitized erythrocytes and a 72 h exposure period. After
the ﬁrst 24 h, PfHRP2 decreased, irrespective of whether susceptible or resistant P. falciparum were exposed to 3, 5 or 7 days of
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Figure 3. Representative images of pyknotic and recovering 3D7 P. falciparum strain after the end of exposure to 2× IC90 of chloroquine for 3 days.
Giemsa-ﬁxed parasites were analysed microscopically every day after 3 days of exposure. Twelve days after removing chloroquine, viable parasites
were observed in the culture. Single images were obtained using a ×100 objective lens. Microscopy was performed using an Olympus BX61 microscope equipped with a visible light laser, and the images were recorded with a digital camera (DP70). This ﬁgure appears in colour in the online version
of JAC and in black and white in the print version of JAC.
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in vivo data indicating that higher but well-tolerated chloroquine
concentrations can effectively treat P. falciparum that are resistant to standard-dose chloroquine.
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berghei-infected mice in which time to recrudescence was approximately 5 days, irrespective of exposure time. However, the
proportion of infections that recrudesced decreased with increasing exposure time in the mice.25
Chloroquine-resistant P. falciparum (FCR3) exposed for 5 days
recovered a median 9 days faster compared with chloroquinesusceptible P. falciparum (3D7) in two independent series,
indicating that this was a real difference. A similar but nonsigniﬁcant 2 day difference was seen after 3 days of exposure.
A larger proportion of chloroquine-resistant parasites becoming
dormant could explain this. As suggested previously, different
parasite densities and/or proportions of different parasite stages
likely to become dormant at the start of treatment could contribute to different numbers of dormant parasites.25 Alternatively,
chloroquine-resistant parasites might be better at becoming
dormant or recover faster. For example, when chloroquinesusceptible and -resistant parasites were treated with high-dose
chloroquine, the in vivo parasite densities decreased at the same
rate. However, slide positivity decreased more slowly in
chloroquine-resistant compared with -susceptible parasites, suggesting that a subpopulation was able to survive for longer.31
Moreover, artemisinin-resistant F32-ART parasites recrudesced
faster compared with artemisinin-susceptible F32-Tanzania
parasites when exposed to artemisinin for the same time and
concentration in vitro.24
During the ﬁrst 24 h, PfHRP2 increased in the
chloroquine-resistant strain (FCR3), indicating increasing parasite
biomass, whilst PfHRP2 decreased in the chloroquine-susceptible
strains (3D7). Artemisinin-induced dormant parasites downregulated most metabolic pathways, with the exception of fatty
acid and pyruvate metabolic pathways, enabling survival.35
When these pathways were inhibited, recrudescence was delayed.35,36 A possible explanation for the difference in PfHRP2 is
that chloroquine-resistant parasites survived for longer by similarly altering their metabolic pathways thereby reducing the
speed by which they were eliminated by chloroquine and enabling a larger proportion of parasites to become dormant. This
could account for the slower in vivo elimination of a subset of
chloroquine-resistant parasites and the more rapid recrudescence discussed in the previous paragraph.31 However, the current experiment used unsynchronized parasites that may well
account for the differences seen.
The main limitations of the study were the use of unsynchronized parasites, use of only two strains and not separating pyknotic parasites to prove that they recover. Unsynchronized
parasites were used to mimic in vivo conditions but this affects
comparisons between strains, as discussed above.37 A study on
various synchronized stages of parasites, several different strains
and a range of parasitized erythrocytes would be valuable but
these were beyond the scope of this study.
To summarize, both chloroquine-susceptible and -resistant P.
falciparum appear to become dormant when exposed to chloroquine. Elimination of dormant parasites is dependent upon T.MIC
and most dormant parasites are eliminated after 7 days of exposure to effective drug concentrations in vitro. This matches

Prolonged chloroquine exposure eliminates dormant P. falciparum

of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial.
J Infect Dis 2011; 203: 109–16.
10 Ursing J, Rombo L, Bergqvist Y et al. High-dose chloroquine for treatment of chloroquine-resistant Plasmodium falciparum malaria. J Infect
Dis 2016; 213: 1315–21.

12 Ursing J, Kofoed P-E, Rodrigues A et al. No seasonal accumulation of
resistant P. falciparum when high-dose chloroquine is used. PLoS One
2009; 4: e6866.
13 Fidock DA, Nomura T, Talley AK et al. Mutations in the P. falciparum
digestive vacuole transmembrane protein PfCRT and evidence for their
role in chloroquine resistance. Mol Cell 2000; 6: 861–71.
14 Martin RE, Marchetti RV, Cowan AI et al. Chloroquine transport via the
malaria parasite’s chloroquine resistance transporter. Science 2009; 325:
1680–2.
15 Summers RL, Dave A, Dolstra TJ et al. Diverse mutational pathways
converge on saturable chloroquine transport via the malaria parasite’s
chloroquine resistance transporter. Proc Natl Acad Sci U S A 2014; 111:
E1759–67.
16 White NJ. Malaria parasite clearance. Malar J 2017; 16: 88.
17 Codd A, Teuscher F, Kyle DE et al. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar J 2011; 10:
56.
18 Hoshen MB, Na-Bangchang K, Stein WD et al. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of ‘dormancy’, a partial cytostatic effect of the drug,
and its implication for treatment regimens. Parasitology 2000; 121:
237–46.
19 LaCrue AN, Scheel M, Kennedy K et al. Effects of artesunate on parasite recrudescence and dormancy in the rodent malaria model
Plasmodium vinckei. PLoS One 2011; 6: e26689.
20 Nakazawa S, Kanbara H, Aikawa M. Plasmodium falciparum: recrudescence of parasites in culture. Exp Parasitol 1995; 81: 556–63.

25 Nakazawa S. Plasmodium berghei NK65: studies on the effect of
treatment duration and inoculum size on recrudescence. Exp Parasitol
2005; 111: 59–63.
26 Trager W, Jensen JB. Human malaria parasites in continuous culture.
Science 1976; 193: 673–5.
27 Noedl H, Bronnert J, Yingyuen K et al. Simple histidine-rich protein 2
double-site sandwich enzyme-linked immunosorbent assay for use in
malaria drug sensitivity testing. Antimicrob Agents Chemother 2005;
49: 3575–7.
28 White NJ. The assessment of antimalarial drug efﬁcacy. Trends
Parasitol 2002; 18: 458–64.
29 WHO. Assessment and Monitoring of Antimalarial Drug Efﬁcacy for
the Treatment of Uncomplicated Malaria. 2003. https://apps.who.int/
iris/handle/10665/68453.
30 Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and
drug resistance. Trends Parasitol 2008; 24: 127–34.
31 Ursing J, Rombo L, Eksborg S et al. High-dose chloroquine for uncomplicated Plasmodium falciparum malaria is well tolerated and causes
similar QT interval prolongation as standard-dose chloroquine in children. Antimicrob Agents Chemother 2020; 64: e01846–19.
32 Mzayek F, Deng H, Mather FJ et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in
healthy volunteers. PLoS Clin Trials 2007; 2: e6.
33 Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during
chronic treatment of patients with rheumatoid arthritis. Eur J Clin
Pharmacol 1992; 42: 429–33.
34 Ursing J, Schmidt BA, Lebbad M et al. Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in
Guinea-Bissau: an effect of high chloroquine dosage? Infect Genet Evol
2007; 7: 555–61.

21 Nakazawa S, Maoka T, Uemura H et al. Malaria parasites giving rise to
recrudescence in vitro. Antimicrob Agents Chemother 2002; 46: 958–65.

35 Chen N, LaCrue AN, Teuscher F et al. Fatty acid synthesis and pyruvate
metabolism pathways remain active in dihydroartemisinin-induced dormant ring stages of Plasmodium falciparum. Antimicrob Agents
Chemother 2014; 58: 4773–81.

22 Teuscher F, Gatton ML, Chen N et al. Artemisinin-induced dormancy
in Plasmodium falciparum: duration, recovery rates, and implications in
treatment failure. J Infect Dis 2010; 202: 1362–8.

36 Peatey CL, Chavchich M, Chen N et al. Mitochondrial membrane potential in a small subset of artemisinin-induced dormant Plasmodium falciparum parasites in vitro. J Infect Dis 2015; 212: 426–34.

23 Thapar MM, Gil JP, Björkman A. In vitro recrudescence of Plasmodium
falciparum parasites suppressed to dormant state by atovaquone alone
and in combination with proguanil. Trans R Soc Trop Med Hyg 2005; 99:
62–70.

37 Carlsson AM, Ngasala BE, Dahlstrom S et al. Plasmodium falciparum
population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J
2011; 10: 380.

1011

Downloaded from https://academic.oup.com/jac/article/77/4/1005/6524118 by Aga Khan University, Health Sciences Library user on 12 May 2022

11 Jovel IT, Kofoed PE, Rombo L et al. Temporal and seasonal changes of
genetic polymorphisms associated with altered drug susceptibility to
chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003
and 2012. Antimicrob Agents Chemother 2015; 59: 872–9.

24 Witkowski B, Lelievre J, Barragan MJ et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother 2010; 54: 1872–7.

